Stellbrink, Hans-Jürgen <br/><br/>
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.  [electronic resource] 

 -  AIDS (London, England)  Jul 2013 
 - 1771-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-5571 
<br/><br/><label>Standard No.: </label>10.1097/QAD.0b013e3283612419  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-HIV Agents--adverse effects<br/>Antiretroviral Therapy, Highly Active--adverse effects<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1--isolation & purification<br/>Heterocyclic Compounds, 3-Ring--adverse effects<br/>Humans<br/>Male<br/>Oxazines<br/>Piperazines<br/>Pyridones<br/>RNA, Viral--blood<br/>Single-Blind Method<br/>Treatment Outcome<br/>Viral Load